SCHEMBL3603992

SCHEMBL3603992

C=Cc1c(C(F)(F)F)nn(C)c1Oc1cc(O[C@@H](C)C(=O)O)c(Cl)cc1Cl

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 3/20 0.37
PTGER4 P35408 1/20 0.37
CYP1A2 P05177 2/20 0.36
CYP2D6 P10635 2/20 0.36
ALDH1A1 P00352 3/20 0.35
KDM4E B2RXH2 2/20 0.35
HSD17B10 Q99714 2/20 0.35
PPARG P37231 3/20 0.35
HPGD P15428 1/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
CYP2C19 P33261 1/20 0.34
CCR1 P32246 2/20 0.33
TDP1 Q9NUW8 1/20 0.33
TSHR P16473 1/20 0.33
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
HTR2B P41595 1/20 0.33
PPARA Q07869 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3605850 0.91 CYP1A2 (0.38) PTGDR2PTGER4CYP1A2CYP2D6ALDH1A1
SCHEMBL3606737 0.89 CYP1A2 (0.39) PTGDR2PTGER4CYP1A2CYP2D6ALDH1A1
SCHEMBL3606733 0.89 CYP1A2 (0.39) PTGDR2PTGER4CYP1A2CYP2D6ALDH1A1
SCHEMBL3603328 0.86 PTGER4 (0.34) PTGDR2PTGER4CYP1A2CYP2D6ALDH1A1
SCHEMBL3603323 0.86 PTGER4 (0.34) PTGDR2PTGER4CYP1A2CYP2D6ALDH1A1
SCHEMBL3608916 0.86 KDM4E (0.39) CYP1A2ALDH1A1KDM4EHSD17B10PPARG
SCHEMBL3605072 0.86 KDM4E (0.39) CYP1A2ALDH1A1KDM4EHSD17B10PPARG
SCHEMBL3610172 0.86 ALDH1A1 (0.39) PTGDR2PTGER4CYP1A2ALDH1A1KDM4E
SCHEMBL3603940 0.86 KDM4E (0.39) CYP1A2ALDH1A1KDM4EHSD17B10PPARG
SCHEMBL3599896 0.85 KDM4E (0.40) PTGDR2PTGER4CYP1A2ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016396-A1 PYRAZOLE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-21 US disclosed
EP-2128138-A1 PYRAZOLE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016396-A1 PYRAZOLE COMPOUND SLC5A1, SLC5A2, GLP1R PTGDR2 2422/4885PTGER4 2282/4885CYP1A2 137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.